Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate‑to‑Severe Atopic Dermatitis involving the Head and Neck Area
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate‑to‑Severe Atopic Dermatitis involving the Head and Neck Area
Francesco Bellinato;Giampiero Girolomoni;
2026-01-01
Abstract
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate‑to‑Severe Atopic Dermatitis involving the Head and Neck Area
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Avallone Lebri Derm Ther 2026 (1).pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
580.8 kB
Formato
Adobe PDF
|
580.8 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
